Arthrex has secured approval from the US Food and Drug Administration (FDA) for its ACL TightRope implant for paediatric indications.

Developed for use in the surgical treatment of orthopaedic injuries, the TightRope implant is claimed to be the first and only fixation device for anterior cruciate ligament (ACL) injuries approved for paediatric application.

With the support of Hospital for Special Surgery (HSS) orthopaedic surgeons Frank Cordasco and Daniel Green, the firm developed all-epiphyseal and transphyseal techniques and instrumentation for ACL surgery.

Arthrex used Cordasco and Green’s advice to develop paediatric and young adolescent-specific instrumentation guides to treat ACL injuries in young athletes.

The all-epiphyseal technique has been developed for patients who are skeletally immature and avoids the paediatric growth plates for ACL repair or reconstruction.

By using paediatric-specific instrumentation guides, surgeons can avoid the growth plate when drilling sockets for the ACL, which will result in lower potential growth disturbance.

With an all-soft-tissue autograft, surgeons can drill across the growth plates to reconstruct the ACL in older adolescent patients approaching skeletal maturation.

Arthrex president and founder Reinhold Schmieding said: “For more than a decade, Arthrex has worked closely with leading orthopaedic surgeons from HSS to develop minimally invasive solutions for pediatric and young adolescent ACL surgery.

“We are proud to partner with surgeons from the Hospital for Special Surgery to design treatment options specifically for ACL injuries in younger patients.

“This is a significant achievement in orthopaedic surgery and another testament to Arthrex’s dedication to its mission of Helping Surgeons Treat Their Patients Better, starting from an early age.”